MyoKardia Receives $38,000,000 New Financing Round

  • Feed Type
  • Date
    9/21/2012
  • Company Name
    MyoKardia
  • Mailing Address
    455 Mission Bay Blvd South San Francisco, CA 94158
  • Company Description
    MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company’s first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
  • Website
    http://www.myokardia.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The initial plan is to go after hypertrophic cardiomyopathy and dilated cardiomyopathy, with a handful of drugs matched up to specifically treat a handful of different genetic forms of the disease.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Undisclosed